Compugen Posts $0.08 Q1 Loss on $2.18M Revenue, Advances 11 Trials
Compugen reported Q1 2026 loss per share of $0.08 on $2.18 million revenue, missing estimates and down from $2.28 million a year earlier. It is enrolling COM701 ovarian cancer trial patients, advancing 11 late-stage rilvegostomig trials with AstraZeneca and has cash runway into 2029 with 6.56 current ratio.
1. Q1 Financial Results
Compugen reported Q1 2026 EPS loss of $0.08 versus a $0.07 consensus estimate, matching last year’s per-share loss, and posted revenue of $2.18 million, down from $2.28 million a year earlier, missing analysts’ revenue forecasts.
2. Clinical Trial Advancement
The company is enrolling patients in its COM701 ovarian cancer trial and advancing its AstraZeneca partnership, currently conducting 11 late-stage rilvegostomig studies with new data expected soon, highlighting momentum in its oncology pipeline.
3. Balance Sheet Strength
With sufficient cash to fund operations into 2029, a debt-to-equity ratio of 0.03 and a current ratio of 6.56, Compugen’s balance sheet remains robust to support ongoing clinical development.